- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Blueprint Medicines Corp (BPMC)
Blueprint Medicines Corp stock price live, this page displays NASDAQ BPMC stock exchange data. View the BPMC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Blueprint Medicines Corp real time stock price chart below.
What Is the Blueprint Medicines Corp Stock Price Today?
The Blueprint Medicines Corp stock price today is 97.17.
What Is the Stock Symbol for Blueprint Medicines Corp?
The stock symbol for Blueprint Medicines Corp is "BPMC."
What Stock Exchange Does Blueprint Medicines Corp Trade On?
Blueprint Medicines Corp is listed and trades on the NASDAQ stock exchange.
Is Blueprint Medicines Corp a Good Stock to Buy?
Determining whether Blueprint Medicines Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BPMC quote. (ISIN: US09627Y1091)
What Is the Blueprint Medicines Corp Stock Price Today?
The Blueprint Medicines Corp stock price today is 97.17.
What Is the Stock Symbol for Blueprint Medicines Corp?
The stock symbol for Blueprint Medicines Corp is "BPMC."
What Stock Exchange Does Blueprint Medicines Corp Trade On?
Blueprint Medicines Corp is listed and trades on the NASDAQ stock exchange.
Is Blueprint Medicines Corp a Good Stock to Buy?
Determining whether Blueprint Medicines Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BPMC quote. (ISIN: US09627Y1091)
Currency in USD
97.17
-1.59(-1.61%)
Closed·
After Hours
96.26-0.91(-0.94%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
97.08
101.34
52 wk Range
73.04
121.90
BPMC Scorecard
Full Analysis
Analysts do not anticipate the company will be profitable this year
BPMC is not included in our AI-picked strategies. Find featured stocks
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
97.08101.34
52 wk Range
73.04121.90
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BPMC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
126.10
Upside
+29.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
Blueprint Medicines Corp Company Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Blueprint Medicines Corp SWOT Analysis
Ayvakit's Triumph | Blueprint Medicines' flagship drug Ayvakit drives impressive revenue growth, with projected sales of $2 billion by 2030 for systemic mastocytosis treatment |
Market Expansion | Explore Blueprint's strategies to broaden Ayvakit's reach, targeting allergists, dermatologists, and gastroenterologists to tap into a global $4 billion peak revenue opportunity |
Pipeline Promise | Delve into BLU-808's potential as Blueprint's next breakthrough, with ongoing studies in allergic conditions poised to open new market frontiers |
Financial Outlook | Analysts set price targets ranging from $83 to $169, reflecting varied perspectives on Blueprint's growth trajectory and market position in precision therapy |
Blueprint Medicines Corp Earnings Call Summary for Q1/2025
- Q1 2025 EPS beat expectations at $0.01 vs -$0.49 forecast; revenue missed at $149.41M vs $156.83M expected
- Full-year revenue guidance raised to $700-$720M; AYVAKIT sales grew 61% YoY
- Stock rose 1.69% pre-market to $91.01; company targets $2B in AYVAKIT revenue by 2030
- CEO Kate Havilland: 'We are exactly where we want to be'; 20% US patient penetration could yield $2B annual revenue
- Challenges include revenue miss, potential market saturation, and intense sector competition
Last Updated: 01/05/2025, 11:28 pm
Read Full TranscriptCompare BPMC to Peers and Sector
Metrics to compare | BPMC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBPMCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −40.3x | −0.6x | −0.5x | |
PEG Ratio | −0.84 | 0.00 | 0.00 | |
Price/Book | 18.3x | 2.5x | 2.6x | |
Price / LTM Sales | 11.2x | 10.4x | 2.9x | |
Upside (Analyst Target) | 33.8% | 351.1% | 53.4% | |
Fair Value Upside | Unlock | 12.5% | 10.2% | Unlock |
Analyst Ratings
16 Buy
5 Hold
1 Sell
Ratings:
22 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 126.10
(+29.77% Upside)
Earnings
Latest Release
May 01, 2025
EPS / Forecast
0.01 / -0.49
Revenue / Forecast
149.41M / 156.83M
People Also Watch
FAQ
What Is the Blueprint Medicines Corp (BPMC) Stock Price Today?
The Blueprint Medicines Corp stock price today is 97.17
What Stock Exchange Does Blueprint Medicines Corp Trade On?
Blueprint Medicines Corp is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Blueprint Medicines Corp?
The stock symbol for Blueprint Medicines Corp is "BPMC."
What Is the Blueprint Medicines Corp Market Cap?
As of today, Blueprint Medicines Corp market cap is 6.28B.
What Is Blueprint Medicines Corp's Earnings Per Share (TTM)?
The Blueprint Medicines Corp EPS (TTM) is -2.45.
When Is the Next Blueprint Medicines Corp Earnings Date?
Blueprint Medicines Corp will release its next earnings report on 29 July 2025.
From a Technical Analysis Perspective, Is BPMC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.